CMS certification 093300
Children's National Hospital
111 Michigan Ave, NW, Washington, DC 20010
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
1,802 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 227 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 538 |
| Clinical | 63 |
| Pediatric Emergency Medicine | 60 |
| Physician Assistant | 50 |
| Pediatric Hematology-Oncology | 48 |
| Dietitian, Registered | 47 |
| Neonatal-Perinatal Medicine | 46 |
| Pediatric Anesthesiology | 45 |
| Pediatric Cardiology | 44 |
| Neurology with Special Qualifications in Child Neurology | 39 |
| Pediatric Critical Care Medicine | 36 |
| Clinical Child & Adolescent | 33 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $497,618
- 2020 $694,173
- 2021 $1.7M
- 2022 $1.5M
- 2023 $1.8M
- 2024 $1.1M
- 2025 $1.5M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $661,200 | 4 |
| Medical devices and supplies on long-term loan | $66,647 | 2 |
| Space rental and facility fees | $35,000 | 9 |
| Speaking, teaching and other services | $13,870 | 7 |
| Debt forgiveness | $4,236 | 6 |
| Education | $2,000 | 1 |
| Consulting fees | $1,000 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $736,012 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. | $654,000 | 2 |
| MED-EL Corporation | $66,140 | 1 |
| Berlin Heart Inc | $15,270 | 2 |
| Qiagen, LLC | $10,000 | 1 |
| National Marrow Donor Program | $8,915 | 5 |
| Siemens Medical Solutions USA, Inc. | $5,191 | 2 |
| Pfizer INC. | $5,000 | 2 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| EPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediat… Novartis Pharmaceuticals Corporation | $326,961 |
| An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizum… Novartis Pharmaceuticals Corporation | $165,296 |
| Omalizumab Before Onset of Exacerbations URI-induc. asthma exacerbation Novartis Pharmaceuticals Corporation | $70,806 |
| An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Tram… Novartis Pharmaceuticals Corporation | $48,300 |
| A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Ad… Novartis Pharmaceuticals Corporation | $36,036 |
| A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or without Hydroxyurea Hydroxycarbam… Novartis Pharmaceuticals Corporation | $22,125 |
| EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study Berlin Heart Inc · NCT05610787 | $15,270 |
| A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pe… Novartis Pharmaceuticals Corporation | $12,028 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Children's National Hospital
Does Children's National Hospital have an emergency room?
Yes. CMS lists emergency services at Children's National Hospital.
Does Children's National Hospital receive money from drug and device companies?
Drug and device makers reported $1.5M in payments to Children's National Hospital for 2025, under the federal Open Payments program. A payment on its own does not show a conflict of interest.